<DOC>
	<DOCNO>NCT02165111</DOCNO>
	<brief_summary>This randomize , double-blinded , clinical trial assess therapeutic efficacy Botulinum toxin A ( Onabotulinumtoxin A ) treat scleroderma-associated Raynaud 's syndrome . Each patient undergo injection treatment dose Botulinum toxin A one randomly-selected hand , contralateral hand inject sterile saline ( placebo ) serve control . Study participant first study visit complete study questionnaire , hand assess clinically digital ulceration , hand undergo non-invasive laser Doppler image assess blood flow . After initial assessment , patient undergo peri-arterial injection Botulinum toxin A one hand , sterile saline solution ( placebo ) , randomize , blind manner . Patient report severity Raynaud 's symptom weekly four month study period . At one month post-injection , patient complete study questionnaire , hand assess clinically digital ulceration , hand undergo non-invasive laser Doppler imaging . At four month post-injection , patient complete study questionnaire , hand assess clinically digital ulceration , hand undergo non-invasive laser Doppler imaging . In addition , patient give option one week post-injection visit , point assessment perform . At conclusion study , unblinding occur .</brief_summary>
	<brief_title>Efficacy Botulinum Toxin In Scleroderma-Associated Raynaud 's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Aged 18 year old Diagnosed scleroderma . Symptoms Raynaud 's syndrome affecting hand ( necessarily equal extent ) Ability return/be available followup evaluation Able willing give inform consent Able speak read English language . A history Myasthenia gravis . Reported allergy hypersensitivity Botulinum toxin preparation . Active infection either hand . Patients ever receive Botulinum toxin vaccine . Pregnant lactating woman . Females unable unwilling maintain abstinence use contraception 28 day follow injection . Patients previously undergone vascular surgery upper extremity , include surgical sympathectomy . Current use aminoglycoside antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Scleroderma , Systemic</keyword>
	<keyword>Raynaud Disease</keyword>
	<keyword>Botulinum Toxins , Type A</keyword>
</DOC>